Korro Bio (NASDAQ:KRRO – Get Free Report) and Xilio Therapeutics (NASDAQ:XLO – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, valuation, dividends, analyst recommendations and risk.
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Korro Bio and Xilio Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Korro Bio | 1 | 2 | 6 | 3 | 2.92 |
| Xilio Therapeutics | 1 | 0 | 0 | 0 | 1.00 |
Korro Bio currently has a consensus price target of $16.50, suggesting a potential upside of 85.19%. Given Korro Bio’s stronger consensus rating and higher possible upside, equities analysts plainly believe Korro Bio is more favorable than Xilio Therapeutics.
Risk and Volatility
Korro Bio has a beta of 3.13, meaning that its stock price is 213% more volatile than the S&P 500. Comparatively, Xilio Therapeutics has a beta of -0.15, meaning that its stock price is 115% less volatile than the S&P 500.
Institutional and Insider Ownership
13.2% of Korro Bio shares are owned by institutional investors. Comparatively, 54.3% of Xilio Therapeutics shares are owned by institutional investors. 4.8% of Korro Bio shares are owned by company insiders. Comparatively, 7.4% of Xilio Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares Korro Bio and Xilio Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Korro Bio | N/A | -114.26% | -68.57% |
| Xilio Therapeutics | -34.06% | -71.99% | -20.43% |
Valuation & Earnings
This table compares Korro Bio and Xilio Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Korro Bio | $6.39 million | 20.54 | -$117.26 million | ($10.00) | -0.89 |
| Xilio Therapeutics | $43.77 million | 1.25 | -$35.04 million | ($1.64) | -5.08 |
Xilio Therapeutics has higher revenue and earnings than Korro Bio. Xilio Therapeutics is trading at a lower price-to-earnings ratio than Korro Bio, indicating that it is currently the more affordable of the two stocks.
About Korro Bio
Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
About Xilio Therapeutics
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
Receive News & Ratings for Korro Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Korro Bio and related companies with MarketBeat.com's FREE daily email newsletter.
